Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. (2020)
Attributed to:
A GMP cell therapy facility to test cell based therapies
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ijid.2020.05.040
PubMed Identifier: 32425638
Publication URI: http://europepmc.org/abstract/MED/32425638
Type: Journal Article/Review
Volume: 96
Parent Publication: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1201-9712